India Caps Profit Margins on 137 Cancer Drugs, Cutting Prices by Up to 70%

India announced on October 18, 2026 that it is widening price controls on anti-cancer medicines, placing a 30% cap on the trade margins — the markups added by wholesalers and retailers — for 137 drugs. The measures, set to take effect on November 9, cover immunotherapy agents and targeted therapies used against more than 20 types of cancer, including breast, prostate, colon, ovarian, and cervical cancers. Patients could see prices fall by up to 70% on some medicines. The government's own estimate puts annual patient savings at up to 25 billion rupees (approximately $263 million). The decision by India's National Pharmaceutical Pricing Authority (NPPA) builds on a 2019 round of controls that capped 42 anti-cancer drugs and cut those prices by up to 90%. India has one of the world's largest cancer burdens and extremely high levels of out-of-pocket health spending, meaning drug costs can be catastrophic for patients and families. The government framed the move as part of a broad push to make life-saving treatment accessible to all income groups. Patient advocacy groups welcomed the step while calling for the same framework to be extended to biologics and immunotherapy drugs not yet covered. The announcement received wide attention across Indian and international health and business media.